| Overview |
| bs-20028R-Cy7 |
| MTA3 Polyclonal Antibody, Cy7 Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Mouse, Rat |
| Human, Dog, Cow, Sheep, Horse, Rabbit |
| Specifications |
| Cy7 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human MTA3 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 57504 |
| Q9BTC8 |
| Nucleus |
| 1110002J22Rik; fj99h01; KIAA1266; Metastasis associated 1 family, member 3; Metastasis associated 3; Metastasis associated family, member 3; Metastasis associated gene 3; Metastasis associated gene family, member 3; Metastasis associated protein MTA3; Metastasis-associated protein MTA3; MGC56396; MGC77410; mKIAA1266; mta1; Mta3; MTA3 metastasis associated 1 family, member 3; Mta3 metastasis associated 3; MTA3_HUMAN; wu:fj99h01; zgc:56396. |
| Plays a role in maintenance of the normal epithelial architecture through the repression of SNAI1 transcription in a histone deacetylase-dependent manner, and thus the regulation of E-cadherin levels. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz